Harmonized-Multinational qEEG Norms (HarMNqEEG)

This paper extends the frequency domain quantitative electroencephalography (qEEG) methods pursuing higher sensitivity to detect Brain Developmental Disorders. Prior qEEG work lacked integration of cross-spectral information omitting important functional connectivity descriptors. Lack of geographical diversity precluded accounting for site-specific variance, increasing qEEG nuisance variance. We ameliorate these weaknesses. i) Create lifespan Riemannian multinational qEEG norms for cross-spectral tensors. These norms result from the HarMNqEEG project fostered by the Global Brain Consortium. We calculate the norms with data from 9 countries, 12 devices, and 14 studies, including 1564 subjects. Instead of raw data, only anonymized metadata and EEG cross-spectral tensors were shared. After visual and automatic quality control, developmental equations for the mean and standard deviation of qEEG traditional and Riemannian DPs were calculated using additive mixed-effects models. We demonstrate qEEG "batch effects" and provide methods to calculate harmonized z-scores. ii) We also show that the multinational harmonized Riemannian norms produce z-scores with increased diagnostic accuracy to predict brain dysfunction at school-age produced by malnutrition only in the first year of life. iii) We offer open code and data to calculate different individual z-scores from the HarMNqEEG dataset. These results contribute to developing bias-free, low-cost neuroimaging technologies applicable in various health settings

Persistence of COVID-19 Symptoms after Recovery in Mexican Population

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease (COVID-19), a highly contagious infectious disease that has caused many deaths worldwide. Despite global efforts, it continues to cause great losses, and leaving multiple unknowns that we must resolve in order to face the pandemic more effectively. One of the questions that has arisen recently is what happens, after recovering from COVID-19. For this reason, the objective of this study is to identify the risk of presenting persistent symptoms in recovered from COVID-19. This case-control study was conducted in one state of Mexico. Initially the data were obtained from the participants, through a questionnaire about symptoms that they had at the moment of the interview. Initially were captured the collected data, to make a dataset. After the pre-processed using the R project tool to eliminate outliers or missing data. Obtained finally a total of 219 participants, 141 recovered and 78 controls. It was used confidence level of 90% and a margin of error of 7%. From results it was obtained that all symptoms have an associated risk in those recovered. The relative risk of the selected symptoms in the recovered patients goes from 3 to 22 times, being infinite for the case of dyspnea, due to the fact that there is no control that presents this symptom at the moment of the interview, followed by the nausea and the anosmia with a RR of 8.5. Therefore, public health strategies must be rethought, to treat or rehabilitate, avoiding chronic problems in patients recovered from COVID-19

Efectos sobre la fertilidad del cerdo de dos candidatos vacunales recombinantes basados en la GnRH

This paper describes for the first time the generation of the K88ab-GnRH hybrid fimbriae, the fusion of N. meningitidis P64k protein (P64k-GnRH), and its evaluation as vaccine candidates to control fertility in mammals. Twenty hybrid male pigs were randomly distributed in four groups: placebos and immunized with K88ab-GnRH, P64k-GnRH and a GnRH analogue (GnRHm1), linked to a tetanus toxoid (TT) T-helper epitope (positive control), respectively. The pigs were immunized at 9-10 weeks of age, using a two-dose scheme, and were sacrificed sixteen weeks later. K88ab-GnRH, P64k-GnRH, and GnRHm1-TT induced higher, similar, and lower testosterone levels in the serum, compared to the placebo, respectively. In the K88ab-GnRH group, the pigs underwent a reduction in testicle size and weight (P < 0.01), and the weight of epididymes compared to the placebo; none of them was able to ejaculate. In the P64k-GnRH group, the pigs had a reduction in testicle weight (P < 0.05), and only one of them was able to ejaculate. The testicles of the pigs immunized with K88ab-GnRH and P64k-GnRH showed structural and functional damage; spermatogenesis was also affected. The accessory sexual glands of the P64k-GnRH group were normal, in contrast to K88ab-GnRH, where interstitial fibrosis was observed. The damage caused by K88ab-GnRH and P64k-GnRH in the target organs evaluated were in all cases lower than the affectations caused by the GnRHm1-TT peptide.En este trabajo se describe, por primera vez, la obtención de la fimbria híbrida K88ab-GnRH, la fusión de la GnRH a la proteína P64k de N. meningitidis (P64k-GnRH) y su evaluación como candidatos vacunales para controlar la fertilidad en mamíferos. Veinte cerdos machos híbridos fueron asignados al azar a cuatro grupos: placebo e inmunizados con K88ab-GnRH, P64k-GnRH y con un péptido análogo de GnRH (GnRHm1), unido a un epítopo T cooperador del toxoide tetánico (TT) (control positivo), respectivamente. Los cerdos se inmunizaron con 9-10 semanas de edad, en un esquema de 2 dosis y se sacrificaron 16 semanas después. K88ab-GnRH, P64k-GnRH y GnRHm1-TT indujeron niveles de testosterona en suero, mayor, similar y menor, comparados con el placebo, respectivamente. En el grupo K88ab-GnRH los cerdos disminuyeron (P < 0,01) el largo y peso de los testículos y el peso de los epidídimos, comparado con el placebo y ninguno llegó a eyacular. En el grupo P64k-GnRH los cerdos disminuyeron el peso de los testículos (P < 0,05), y sólo uno llegó a eyacular. Los testículos de los cerdos inmunizados con K88ab-GnRH y P64k-GnRH mostraron daños estructurales, funcionales y afectación de la espermatogénesis. Las glándulas sexuales accesorias del grupo P64k-GnRH estaban normales a diferencia de K88ab-GnRH, en las que se observó fibrosis intersticial. Los daños provocados por K88ab-GnRH y P64k-GnRH en los órganos diana evaluados, resultaron inferiores en todos los casos, a las afectaciones que generó el péptido GnRHm1-TT

A clinical pathway for community-acquired pneumonia: an observational cohort study

<p>Abstract</p> <p>Background</p> <p>Six hospitals instituted a voluntary, system-wide, pathway for community acquired pneumonia (CAP). We proposed this study to determine the impact of pathway antibiotics on patient survival, hospital length of stay (LOS), and total hospital cost.</p> <p>Methods</p> <p>Data were collected for adults from six U.S. hospitals with a principal CAP discharge diagnosis code, a chest infiltrate, and medical notes indicative of CAP from 2005-2007. Pathway and non-pathway cohorts were assigned according to antibiotics received within 48 hours of admission. Pathway antibiotics included levofloxacin 750 mg monotherapy or ceftriaxone 1000 mg plus azithromycin 500 mg daily. Multivariable regression models assessed 90-day mortality, hospital LOS, total hospital cost, and total pharmacy cost.</p> <p>Results</p> <p>Overall, 792 patients met study criteria. Of these, 505 (64%) received pathway antibiotics and 287 (36%) received non-pathway antibiotics. Adjusted means and p-values were derived from Least Squares regression models that included Pneumonia Severity Index risk class, patient age, heart failure, chronic obstructive pulmonary disease, and admitting hospital as covariates. After adjustment, patients who received pathway antibiotics experienced lower adjusted 90-day mortality (<it>p </it>= 0.02), shorter mean hospital LOS (3.9 vs. 5.0 days, <it>p </it>< 0.01), lower mean hospital costs ($2,485 vs.$3,281, <it>p </it>= 0.02), and similar mean pharmacy costs ($356 vs.$442, <it>p </it>= 0.11).</p> <p>Conclusions</p> <p>Pathway antibiotics were associated with improved patient survival, hospital LOS, and total hospital cost for patients admitted to the hospital with CAP.</p

Gradual reduction of testosterone using a gonadotropin-releasing hormone vaccination delays castration resistance in a prostate cancer model

In a previous study aimed to design a novel prostate cancer vaccine, the authors of the present study demonstrated the advantage of combining the adjuvants Montanide ISA 51 with very small size proteoliposomes (VSSP) to promote a significant humoral immune response to gonadotropin‑releasing hormone (GnRH) in healthy animals. The present study compared the efficacy of this vaccine formulation versus the standard treatment currently available in terms of preventing the development of tumors in DD/S mice injected with Shionogi carcinoma (SC) 115 cells. The results demonstrated that 5 non‑vaccinated control mice exhibited a fast tumor growth, and succumbed to the disease within 19‑31 days. Mice immunized with the GnRH/Montanide ISA 51/VSSP vaccine exhibited a moderate decline in testosterone levels that was associated with a decrease in anti‑GnRH antibody titers, which lead to a sustained tumor growth inhibition. In total, 2 mice in the immunized group exhibited complete remission of the tumor for the duration of the present study. In addition, castrated mice, which were used as a control for standard hormonal therapy, exhibited an accelerated decrease in tumor size. However, tumor relapse was observed between days 50 and 54, and between days 65 and 85, following the injection of SC 155 cells. Therefore, these mice were sacrificed at day 90. The present study concludes that the slow and moderate reduction of testosterone levels observed using the GnRH‑based vaccine may delay the appearance of castration resistance in a Shionogi prostate cancer model. These findings suggest that this vaccine may be used to delay castration resistance in patients with prostate cancer.The authors would like to thank the Union for International Cancer Control (Geneva, Switzerland; grant no., YY1/09/008/2009) for the fellowship received to support the present study. The authors would also like to thank the researchers at the Trev and Joyce Deeley Research Centre (Victoria, Canada), British Columbia Cancer Research Centre (Vancouver, Canada) and University of Victoria (Victoria, Canada), particularly Professor Brad Nelson, Dr Julian Lum and Dr John Webb, for purchasing the mice and providing the laboratory facilities required to conduct the present study.http://www.spandidos-publications.com/or/2017-02-27am2016Mammal Research Institut

A new species of Charadrahyla (Anura: Hylidae) from the cloud forest of western Oaxaca, Mexico

Jiménez-Arcos, Víctor H., Calzada-Arciniega, Rafael Alejandro, Alfaro-Juantorena, Liz A., Vázquez-Reyes, Leopoldo D., Blair, Christopher, Parra-Olea, Gabriela (2019): A new species of Charadrahyla (Anura: Hylidae) from the cloud forest of western Oaxaca, Mexico. Zootaxa 4554 (2): 371-385, DOI: https://doi.org/10.11646/zootaxa.4554.2.